Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms
作者: Vincenza CifarelliLaura M. LashingerKaylyn L. DevlinSarah M. DunlapJennifer HuangRudolf KaaksMichael N. PollakStephen D. Hursting
作者单位: 11Department of Medicine, Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO
22Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX
33Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX
44Division of Epidemiology, German Cancer Research Center, Heidelberg, Germany
55Departments of Medicine and Oncology, McGill University, Montreal, Canada
66Department of Nutrition, University of North Carolina, Chapel Hill, NC
77Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
刊名: Diabetes, 2015, Vol.64 (5), pp.1632-1642
来源数据库: Duke University Press
DOI: 10.2337/db14-1132
原始语种摘要: Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin’s PC growth inhibition in the context of a prediabetic state is unknown. We used a Panc02 pancreatic tumor cell transplant model in diet-induced obese (DIO) C57BL/6 mice to compare the effects of metformin and the direct mammalian target of rapamycin (mTOR) inhibitor rapamycin on PC growth, glucose regulation, mTOR pathway signaling, and candidate microRNA (miR) expression. In DIO/prediabetic mice, metformin and rapamycin significantly reduced pancreatic tumor growth and mTOR-related signaling. The rapamycin effects centered on decreased mTOR-regulated growth and survival signaling, including increased expression of let-7b...
全文获取路径: Duke University Press 
影响因子:7.895 (2012)

  • metformin 二甲双胍
  • rapamycin 雷帕霉素
  • diabetes 糖尿病
  • pancreatic 胰的
  • glucose 葡萄糖
  • insulin 胰岛素
  • reduced 减缩的
  • growth 生长
  • intervention 
  • expression 表示